InfuSystem (INFU) Competitors

InfuSystem (NYSE:INFU) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Is INFU or SIBN more profitable?

InfuSystem has a net margin of 1.12% compared to SiBone's net margin of -12.83%. InfuSystem's return on equity of 2.78% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
SiBone	-12.83%	-14.20%	-10.38%

Does the media prefer INFU or SIBN?

In the previous week, SiBone had 7 more articles in the media than InfuSystem. MarketBeat recorded 8 mentions for SiBone and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.00 beat SiBone's score of -0.10 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Positive
SiBone	Neutral

Which has better valuation & earnings, INFU or SIBN?

InfuSystem has higher earnings, but lower revenue than SiBone. SiBone is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$139.89M	1.40	$870K	$0.23	41.61
SiBone	$167.18M	4.23	-$30.91M	-$0.56	-29.27

Do analysts recommend INFU or SIBN?

InfuSystem currently has a consensus target price of $12.50, suggesting a potential upside of 30.62%. SiBone has a consensus target price of $23.67, suggesting a potential upside of 44.40%. Given SiBone's higher probable upside, analysts plainly believe SiBone is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	4.00
SiBone	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, INFU or SIBN?

InfuSystem has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Do insiders & institutionals hold more shares of INFU or SIBN?

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 11.4% of InfuSystem shares are owned by company insiders. Comparatively, 4.0% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

InfuSystem beats SiBone on 11 of the 17 factors compared between the two stocks.